Research

Hormonal

GLP-1 receptor agonists (GLP-1 RAs) improve skeletal muscle mitochondrial morphology, area, and number in animal models of obesity and type 2 diabetes, but their effect on mitochondrial respiration and mass is inconsistent or neutral.

Current evidence for GLP-1 RAs improving muscle mitochondria comes exclusively from animal and cell studies, not humans. While these studies show improved mitochondrial structure, they do not guarantee preserved muscle mass in people. To protect muscle while using GLP-1s for weight loss, prioritize resistance training and adequate protein intake, as the drug's direct benefit to human muscle mitochondria is not yet proven.

LimitedQualifiesLOW confidence
The emerging evidence suggests that GLP-1 RAs increase mitochondrial area, number and morphology (i.e., reduces swelling). Data are conflicting on the effect of GLP-1 RAs upon mitochondrial mass, respiration and the expression of uncoupling proteins and PGC-1α.
Victoria J. Old et al. · Journal of Cachexia Sarcopenia and Muscle · 2025

Why this rating

The review includes only preclinical (animal/in vitro) studies, with no human data, and high risk of bias in included trials.

Source

The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review

Victoria J. Old et al. · Journal of Cachexia Sarcopenia and Muscle · 2025

DOI 10.1002/jcsm.13677

systematic_reviewCited 44×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →